User:Mr. Ibrahem/Inotuzumab ozogamicin

Inotuzumab ozogamicin, sold under the brand name Besponsa, is a medication used to treat B-cell precursor acute lymphoblastic leukemia (ALL). It is used when the cancer cells are CD22 positive and other treatments have failed. It is given by gradual injection into a vein.

Common side effects include low platelets, low white blood cells, infection, low red blood cells, tiredness, bleeding, fever, nausea, headache, and liver problems. Liver problems may include hepatic veno-occlusive disease. Other side effects may include QT prolongation and infertility. Use in pregnancy may harm the baby. It is a monoclonal antibody linked to N-acetyl-γ-calicheamicin. The antibody attaches to cells that express CD22 which brings about their death.

Inotuzumab ozogamicin was approved for medical use in the United States and Europe in 2017. In the United Kingdom it costs the NHS about £8,000 per 1 mg dose as of 2021. This amount in the United States costs about 24,000 USD.